Premier Veterinary Group
Advancing Research in Feline Cardiology
Premier Veterinary Group is participating in an international, multicenter clinical study evaluating an investigational therapy for cats diagnosed with heart disease. This research aims to advance treatment options and improve outcomes for feline patients with cardiac conditions.
Study Overview
The Feline Heart Study is a double-blind, placebo-controlled clinical trial, designed to assess the safety and effectiveness of an investigational medication in cats with heart disease. This study follows rigorous clinical research standards and includes comprehensive cardiology evaluations throughout participation.
All study-related diagnostics, evaluations, and medications are provided at no cost for enrolled patients.
Why This Study Matters
Heart disease is a common and often progressive condition in cats. Clinical research plays a critical role in expanding therapeutic options and refining standards of care. Participation in this study contributes to the advancement of feline cardiology while providing enrolled patients with consistent monitoring by veterinary cardiology specialists.
Study-Provided Services
Eligible patients enrolled in the study may receive:
Comprehensive cardiology examinations
Echocardiography
Electrocardiography (ECG/EKG)
Thoracic radiographs, as indicated
Bloodwork and urinalysis
Investigational medication or placebo
All study-related services are provided at no cost for the duration of the trial.
Eligibility Criteria
Patients may qualify for enrollment if they meet the following general criteria:
Diagnosis of heart disease within the past 60 days
At least 12 months of age and weighing ≥ 2 kg (4.4 lbs)
Clinically stable at time of enrollment
Not diabetic or receiving insulin therapy
Not pregnant, nursing, or intended for breeding
Final eligibility is determined following a formal screening evaluation.
Study Participation Details
Enrolled patients will:
Receive daily oral administration of study medication or placebo
Continue to receive standard-of-care cardiac management
Return for scheduled follow-up visits throughout the study period
Participation typically includes 6–7 visits and may last up to 18 months, depending on individual patient factors.
Placebo-Controlled Design
This study utilizes a placebo-controlled design, with enrolled patients randomized to receive either the investigational medication or placebo. All patients continue to receive standard-of-care therapy consistent with current veterinary cardiology guidelines, regardless of group assignment.
Referral & Enrollment Process
Referring veterinarians may submit a prescreening questionnaire to determine whether a patient may be eligible for formal screening. Patients meeting prescreen criteria will be scheduled for a cardiology evaluation at a participating study site to confirm enrollment eligibility.
Questions or More Information
For questions or additional information regarding the Feline Heart Study, please email [email protected]
